Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. (4th July 2017)

• Record Type: Journal Article
• Authors: Russi, Alberto; Damuzzo, Vera; Chiumente, Marco; Pigozzo, Jacopo; Cesca, Marco; Chiarion-Sileni, Vanna; Palozzo, Angelo Claudio
• Is Part Of: Journal of chemotherapy. Volume 29:Number 4(2017)
• Page Start: 245
• Page End: 251
• Publication Date: 2017-07-04
• Subjects: Oncology -- Ipilimumab -- Melanoma -- Monoclonal antibodies -- Registries -- Retrospective studies; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2017.1311444
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : In patients with metastatic melanoma, ipilimumab has been shown to improve long-term survival. This observational multicenter study reports clinical outcomes of 418 patients treated with second-line ipilimumab from February 2013 to August 2014. Median overall survival (OS) was 6.43 months (95%CI: 5.45–7.42; n = 300), while median progression-free survival (PFS) was 3.7 months (95%CI: 3.23–4.17; n = 188). Demographic factors, such as sex or number of previous therapies did not affect OS. Survival was shorter in patients with ECOG > 0 (Eastern Cooperative Oncology Group, Performance Status) ( p < 0.001), while a longer OS was found in patients who completed all four therapy cycles ( p < 0.001). Adverse events of any grade were reported for 66% of patients (mainly cutaneous and gastrointestinal), but most were low grade and easily managed. Adverse events of grades 3–4 were observed in 13% of patients. This study confirmed the efficacy and safety of this treatment in real practice.